Arca
Skip to content
Tools
Tools

SOST: Sclerostin

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. .

  • Drugs that act on it: 5
  • Approved: 1
  • In phases 1 to 3: 4
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on SOST, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 3
  • Other 2

Approved1

  • Romosozumab

Phase 31

  • Setrusumab

Phase 21

  • Blosozumab

Phase 12

  • AMG-167
  • Anti-sclerostin

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

The landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Sclerostin inhibitor.
RomosozumabBoxed warningApprovedAmgenAntibodyInhibitor23
SetrusumabPhase 3Ultragenyx PharmaceuticalAntibodyInhibitor3
BlosozumabPhase 2Eli LillyAntibodyInhibitor0
AMG-167Phase 1AmgenOtherInhibitor0
Anti-sclerostinPhase 1—OtherInhibitor0

Open trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 11 in all, from ClinicalTrials.gov.
Romosozumab and Denosumab Combination Therapy for OsteoporosisRomosozumabPhase 4Not yet recruitingMassachusetts General HospitalNov 2, 2026
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsRomosozumabPhase 1RecruitingAmgenSep 10, 2026
A Study of Romosozumab in People With Breast Cancer and OsteoporosisRomosozumabPhase 2RecruitingMemorial Sloan Kettering Cancer CenterAug 20, 2026
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDRomosozumabPhase 4Not yet recruitingSahlgrenska University HospitalAug 19, 2026
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 YearsRomosozumabPhase 4Not yet recruitingTuen Mun HospitalAug 11, 2026
MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal OsteoporosisRomosozumabNot applicableRecruitingIstituto Auxologico ItalianoJun 1, 2026
Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy SubjectsRomosozumabPhase 1Enrolling by invitationShenzhen Salubris Pharmaceuticals Co., Ltd.Feb 3, 2026
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaRomosozumabPhase 3RecruitingAmgenJan 26, 2026
Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaSetrusumabPhase 3Active, not recruitingUltragenyx Pharmaceutical IncOct 10, 2024
Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis ImperfectaSetrusumabPhase 3Active, not recruitingUltragenyx Pharmaceutical IncMar 14, 2023
Setrusumab vs Placebo for Osteogenesis ImperfectaSetrusumabPhase 2 / Phase 3Active, not recruitingUltragenyx Pharmaceutical IncNov 18, 2021

Diseases most associated with it

Open Targets association score, 0 to 1; all associations
Sclerosteosis 1
0.70
Craniodiaphyseal dysplasia
0.65
Sclerosteosis
0.61
Hyperostosis corticalis generalisata
0.60
Bone disorder
0.38
Heart disorder
0.32

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3580487, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9BQB4, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.